Performance and Safety of Bone Substitute MBCP-FS in Maxillary Sinus Lift Procedures

NCT ID: NCT00163605

Last Updated: 2007-11-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the performance and to monitor the safety of the bone substitute Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS) in Sinus Lift Procedures . This study will be conducted in two parts: part A evaluates safety and performance of MBCP-FS in bone regeneration i.e. the amount of new bone that is formed and its suitability for dental implant placement. Part B is designed to evaluate long-term safety and performance of the product, i.e. whether the newly-formed bone is suitable to retain implants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sinus Implant Reconstruction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Sinus augmentation Alloplastic bone substitute Hydroxyl apatite

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent obtained from the subject prior to participation in the study
* At least 18 years of age
* Partially or totally edentulous with an atrophic posterior maxilla requiring unilateral or bilateral sinus lift before dental implant placement
* In case of bilateral sinus lifts, both sides are operated on the same day.
* Subjects with remaining minimal maxillary bone height between 2 mm and 5 mm at the site with minimal height in the area where implants are planned, and a remaining maxillary bone thickness \>= 5 mm in the area where implants are planned

Exclusion Criteria

* Previous or coeval major surgical intervention in the targeted area, or major surgical intervention in the targeted area planned within the next 18 months (like Caldwell Luc) (minor interventions like surgical tooth extraction or root tip resections are allowed)
* Surgical tooth extraction in the targeted area less than three months before the SLP
* Maxillary and sinus disorders including: acute sinusitis, chronic sinus pathology, retained root tips, polyps, tumors, and cysts in antral cavity or odontogenic cysts, alveolar scar ablation
* Major occlusal disturbance, like severe bruxism
* Uncontrolled\* periodontal disease
* An inadequate interarch distance requiring an oppositional graft
* Immune system disorders, immunodeficiency or immunosuppression
* Known coagulation disorder
* Uncontrolled\* diabetes mellitus
* Severe hyperparathyroidism
* Receiving long-term anti-inflammatory treatment with NSAIDs or corticosteroids
* Chemotherapy current or in the last three months
* Having undergone maxillary radiation therapy
* Known hypersensitivity to aprotinin or to other components of the investigational product
* Abuse of alcohol or drugs or tobacco consumption of more than 5 cigarettes per day at study start
* Non-compliant for future dental hygiene
* Severely compromised physical and psychological health, that in the investigators opinion will affect patient compliance
* Any contra-indications to the use of MBCP, which are defined as osteomyelitis, degenerative bone disease or necrosis of the recipient site
* Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days
* Pregnant or lactating, or intending to become pregnant during the study period

* Uncontrolled = not treated or not stabilized after treatment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Baxter Healthcare Corporation

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Baxter BioScience Investigator

Role: PRINCIPAL_INVESTIGATOR

Baxter BioScience

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Klinik für Mund-, Kiefer- und Gesichtschirurgie des Helios-Klinikums Erfurt

Erfurt, , Germany

Site Status

Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie der Universität Erlangen-Nürnberg

Erlangen, , Germany

Site Status

Universitätsklinikum Schleswig Holstein, Campus Kiel

Kiel, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

570201

Identifier Type: -

Identifier Source: org_study_id